Hansen Medical's Magellan(TM) Robotic System to Be Featured at 36th
Annual Charing Cross International Symposium
MOUNTAIN VIEW, CA--(Marketwired - Apr 3, 2014) - Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in Intravascular Robotics,
today announced it will exhibit its Magellan™ Robotic System at the
36th Annual Charing Cross International Symposium (CX 2014) from
April 5 - 8 at Grand Hall Olympia in London, United Kingdom. The
Company will be conducting product demonstrations and exhibiting
the Magellan Robotic System at Booth 221.
In addition to these product demonstrations, multiple
presentations discussing the Magellan Robotic System are also
planned during the symposium. On Saturday, April 5 at 11:30am,
five physicians (Alan Lumsden, M.D., Houston Methodist Hospital,
Houston; Professor Jean-Pierre Becquemin, M.D., Henri Mondor
Hospital, Cretéil, France; Thomas Nolte, M.D., Bad Bevensen Heart
and Vascular Center, Germany ; Professor Nabil Chakfé, M.D.,
University Hospital Strasbourg, France; Professor Nicholas
Cheshire, M.D., St. Mary's Hospital, London) will discuss their
clinical experiences with Magellan in a symposium titled
Clinical Experiences with Intravascular Robotics, during
the "CX Vascular and Advanced Imaging Course" parallel session in
the Grey Learning Centre.
On Sunday, April 6 at 3:20pm, Francis MacNamara, VP of Advanced
Technology at Hansen Medical, has been invited to present a talk
titled Robotic Endovascular Navigation: Latest Developments and
New Technologies, during the "CX Innovation Showcase" parallel
session.
"The Charing Cross International Symposium is one of the year's
most important vascular conferences and we are pleased to have our
Magellan System highlighted prominently in numerous settings
throughout the conference," said Chris Lowe, Interim CEO of Hansen
Medical. "The increasing level of activity around intravascular
robotics at global, vascular conferences reflects the continuing
momentum we are seeing with the Magellan System."
About the Magellan™ Robotic System Hansen Medical's Magellan
Robotic System is intended to be used to facilitate navigation in
the peripheral vasculature and subsequently provide a conduit for
manual placement of therapeutic devices. The Magellan Robotic
System is designed to deliver improved predictability, control and
catheter stability to endovascular procedures. Since its commercial
introduction in the U.S. and Europe, the Magellan Robotic System
has demonstrated its clinical versatility in many cases in a broad
variety of peripheral vascular procedure types in centers across
the U.S. and Europe.
The Magellan 9Fr Robotic Catheter allows for independent,
robotic control of the distal tip of two telescoping catheters (an
outer Guide and an inner Leader catheter), as well as robotic
manipulation of standard guidewires. The Magellan 6Fr Robotic
Catheter also provides independent robotic control of two separate
bend sites on a single catheter, as well as robotic manipulation of
standard guidewires. This smaller catheter design may be
preferred by certain physicians who prefer a smaller diameter
vessel incision site, or in procedures in smaller
vessels.
About Hansen Medical, Inc. Hansen Medical, Inc., based in
Mountain View, California, is a global leader in Intravascular
Robotics, developing products and technology designed to enable the
accurate positioning, manipulation and control of catheters and
catheter-based technologies. The Company's Magellan™ Robotic
System, 9Fr Magellan™ Robotic Catheter, Magellan™ 6Fr Robotic
Catheter, and related accessories are intended to facilitate
navigation to anatomical targets in the peripheral vasculature and
subsequently provide a conduit for manual placement of therapeutic
devices. The Magellan 9Fr Robotic Catheter has undergone both CE
marking and 510(k) clearance and is commercially available in the
European Union, and the U.S. The Magellan 6Fr Robotic Catheter has
undergone 510(k) clearance in the U.S. and is in limited release
for the next several months in anticipation of more wide-scale
commercially availability later in 2014. In the European
Union, the Company's Sensei® X Robotic Catheter System and Artisan®
and Artisan Extend® Control Catheters are cleared for use during
electrophysiology (EP) procedures, such as guiding catheters in the
treatment of atrial fibrillation (AF), and the Lynx® Robotic
Ablation Catheter is cleared for the treatment of AF. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the U.S., the
Company's Sensei X Robotic Catheter System and Artisan and Artisan
Extend Control Catheters are cleared by the U.S. Food and Drug
Administration for manipulation and control of certain mapping
catheters in EP procedures. In the U.S., the Sensei X Robotic
Catheter System is not approved for use in guiding ablation
procedures; this use remains experimental. The U.S. product
labeling therefore provides that the safety and effectiveness of
the Sensei X Robotic Catheter System and Artisan and Artisan Extend
Control Catheter for use with cardiac ablation catheters in the
treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
www.hansenmedical.com.
Forward-Looking Statements This press release contains
forward-looking statements regarding, among other things,
statements relating to goals, plans, objectives, milestones and
future events. All statements, other than statements of historical
fact, are statements that could be deemed forward-looking
statements, including statements containing the words "plan,"
"expects," "potential," "believes," "goal," "estimate,"
"anticipates," and similar words. These statements are based on the
current estimates and assumptions of our management as of the date
of this press release and are subject to risks, uncertainties,
changes in circumstances and other factors that may cause actual
results to differ materially from the information expressed or
implied by forward-looking statements made in this press release.
Examples of such statements include statements about the potential
benefits, market size, timing and results of commercializing our
Magellan 6Fr Robotic Catheter. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for
the sales cycle for newly introduced products; the rate of adoption
of our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our
products; competition from other companies; our ability to recruit
and retain key personnel; our ability to manage expenses and cash
flow, and obtain additional financing; and other risks more fully
described in the "Risk Factors" section of our Annual Report on
Form 10K for the year ended December 31, 2013 filed with the SEC on
March 9, 2014 and the risks discussed in our other reports filed
with the SEC. Given these uncertainties, you should not place undue
reliance on the forward-looking statements in this press release.
We undertake no obligation to revise or update information herein
to reflect events or circumstances in the future, even if new
information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan
and NorthStar are trademarks of Hansen Medical, Inc. in the United
States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial Officer
Hansen Medical, Inc. 650.404.5800
Westwicke Partners, LLC. Mark Klausner 443.213.0501 Email
Contact Mike Piccinino, CFA 443.213.0509
Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024